Gilad Rabina - research works

We included 86 eyes of 78 patients.

ODR of SRF and PED were not significantly associated with deltaBCVA.

A total of 55 patients with mMNV, with a mean age of 65.7 ± 14.5 years, met the inclusion criteria.

The mean number of injections was significantly higher during the first year of follow-up with 8.78 ± 2.90 within the 1st year versus 3.45 ± 4.40 during the 2nd year (p = 0.037).

Visual acuity (VA) remained relatively stable throughout the follow-up (p = 0.902), with most patients maintaining their vision or experiencing a loss of up to 5 Snellen letters.

Similarly, all macular measurements were significantly higher in the PCME eye compared to the contralateral eye (p < 0.001 for all).

In terms of RNFL measurements, the PCME eyes had greater global (p < 0.001), superonasal (p = 0.001) and superotemporal (p = 0.005) thickness values.

PCME eyes demonstrated a significant decrease in thickness for all macular and RNFL parameters following resolution of CME (p < 0.05 for all).

A total of 263 eyes of 263 patients with a mean age of 71.5 ± 11.2 years of which 50% were of male gender met the inclusion criteria.

There was not a significant difference in mean age (p = 0.634) and gender (p = 0.269) between the groups.

The difference between the rate of change in BCVA per year was insignificant between groups (p = 0.414).

In multivariate analysis, baseline BCVA was the single significant predictor for switch (beta 0.137, p = 0.035).

During the COVID-19 period, the mean number of anti-VEGF injections was significantly lower than the corresponding pre-COVID-19 and post-COVID-19 periods (5.55 compared to 6.13 and 6.60, respectively p < 0.01).

Baseline BCVA (0.825, p < 0.001), number of injections (-0.007, p < 0.001), gender (-0.027, p = 0.037) and age (0.004, p < 0.001) were shown to be significant predictors of final BCVA.

Best corrected visual acuity (BCVA) remained stable for the first four years of follow up, with a significant deterioration in BCVA thereafter.

Baseline BCVA was a significant predictor of final BCVA (p < 0.001).

Subretinal fluid (SRF) at presentation was significantly associated with decreased inactivation index (p < 0.05).

Worse baseline BCVA, SRF and pigment epithelium detachment (PED), male sex, and younger patient age were associated with increased risk for recurrence after first inactivation (p < 0.05).

Baseline best corrected visual acuity (BCVA) among patients in 2019 and 2020 was 0.52 ± 0.44, 0.45 ± 0.43 (logarithm of the minimal angle of resolution, respectively).

There was no significant difference between the years 2020 and 2019 in baseline BCVA (p = 0.07).

Baseline BCVA (p < 0.01) was the only significant predictor of final BCVA.

Number of injections, age, gender, and the year were not found as predictors of final BCVA.

A total of 86 eyes of 85 consecutive patients, with mean age of 80.31 ± 8.06 and mean best-corrected visual acuity of 1.17 ± 0.58 logarithm of the minimal angle of resolution.

Two different subtypes of FTMHs were identified: tractional and degenerative.

Fifty (58%) degenerative FTMHs characterized with inverted trapezoid appearance and 36 (42%) tractional FTMHs characterized with hourglass appearance.

The presence of epiretinal membrane and pigment epithelium detachment where significantly higher in tractional FTMHs (P = 0.02, 0.03, respectively).

Conversely, pars plana vitrectomy (PPV) for dislocated fragments of lens material, age > 70 years, gender, axial length, degree of surgeon, corneal suturing, and anterior chamber lens implantation were not found to have significant associations with low visual outcomes ( P > 0.05).